EP4234523A1 — Semifluorinated compounds for ophthalmic administration
Assigned to Novaliq GmbH · Expires 2023-08-30 · 3y expired
What this patent protects
The divisional application relates to liquid compositions comprising semifluorinated derivatives of the formula CF<sub>3</sub>-(CF<sub>2</sub>)<sub>n</sub>-CH(CH<sub>3</sub>)-(CH<sub>2</sub>)<sub>m</sub>-CH&l…
USPTO Abstract
The divisional application relates to liquid compositions comprising semifluorinated derivatives of the formula CF<sub>3</sub>-(CF<sub>2</sub>)<sub>n</sub>-CH(CH<sub>3</sub>)-(CH<sub>2</sub>)<sub>m</sub>-CH<sub>3</sub> wherein n represents 3-5 and m is 1-5. The compositions are useful for topical administration to the eye, e.g. for the treatment of dry eye disease (keratoconjunctivitis sicca). A kit comprising the composition and a container for holding the composition is also provided.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.